Natco Pharma Limited

Price Chart

Risk-Adjusted Performance

Natco Pharma Limited (NATCOPHARM) Price Performance

Natco Pharma Limited (NATCOPHARM) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR1119.70, up 3.03% from the previous close.

Over the past year, NATCOPHARM has traded between a low of INR791.52 and a high of INR1123.70. The stock has gained 19.0% over this period. It is currently 41.5% above its 52-week low.

Natco Pharma Limited has a market capitalization of $194.66B, with a price-to-earnings ratio of 12.49 and a dividend yield of 0.46%.

About Natco Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.